KALM Therapeutics
Company

KALM Therapeutics

Biotechnology Research 4 employees
Employees
4
Contacts
3
Emails
3
Phones
2

KALM Therapeutics Overview

Industry
Biotechnology Research
Employees
4
Funding
590.4K
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About KALM Therapeutics

Pioneering a Breakthrough in Eczema and Psoriasis Treatment Kalm Therapeutics is developing the 1st Prescription Patch treatment for eczema and psoriasis. Protect and Treat The Kalm Patch will cover the affected skin, protecting it from scratching, infection and moisture loss; all of which are known disease drivers. In addition, our proprietary formulation delivers a continuous therapeutic dose to the epidermis over 24 hours, which will provide optimal efficacy. Our natural active ingredient is a proven safe, anti-inflammatory small molecule. This once-a-day patch will be a giant leap from harmful steroids and other topical creams, which provide no protection to the skin, require multiple doses per day, and deliver uneven dose levels to the epidermis.

KALM Therapeutics Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
2
50.0% coverage

KALM Therapeutics Org Chart

Sample employees and titles
Name Title Contact
Anuj (Aj) Singhal Founder/ceo Kalm Therapeutics, CEO Pop Therapeutics, Manager Drug Discovery at Cfd Research Corporation
Email
Tacey Viegas Chief Development Officer at Kalm Therapeutics, Inc.
Email Phone
Vincent Harrand
Email Phone
James Gilbert Pediatric Surgeon, Director of Pediatric Surgery at Huntsville Hospital, Founder and Senior Partner of Tennessee Valley Pediatric Surgery
View

Employees by Management Level

Executive 3 profiles

Compare Similar Companies to KALM Therapeutics